CHMP recommends revoking marketing authorisation for TAVNEOS® in the European Union Life Science Investing
HCW Biologics Announces 1-for-6 Reverse Stock Split Effective on June 30, 2026 Life Science Investing
Medicenna Therapeutics Reports Fiscal Year 2026 Financial Results and Operational Highlights Life Science Investing
Nkarta to Participate in H.C. Wainwright 4th Annual Cell Therapy Virtual Conference Life Science Investing
Life Sciences Virtual Investor Forum Presentations Now Available for On-Demand Viewing Life Science Investing
Incyte Announces Positive CHMP Opinion for Opzelura® Cream for the Treatment of Adults with Moderate Atopic Dermatitis Life Science Investing
Axsome Therapeutics Initiates FOCUS-3 Phase 3 Trial of Solriamfetol in Adolescents with Attention Deficit Hyperactivity Disorder Life Science Investing
Taysha Gene Therapies Announces Multiple Presentations Highlighting its TSHA-102 Clinical Program at the 2026 IRSF Rett Syndrome Scientific Meeting Life Science Investing
NRx Pharmaceuticals Responds to Recent Public Statements Regarding Kadima Dispute Life Science Investing
